These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 19876723)
1. Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs. Dubois A; Gsteiger S; Pigeolet E; Mentré F Pharm Res; 2010 Jan; 27(1):92-104. PubMed ID: 19876723 [TBL] [Abstract][Full Text] [Related]
2. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm. Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036 [TBL] [Abstract][Full Text] [Related]
3. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials. Panhard X; Mentré F Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916 [TBL] [Abstract][Full Text] [Related]
4. New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling. Loingeville F; Bertrand J; Nguyen TT; Sharan S; Feng K; Sun W; Han J; Grosser S; Zhao L; Fang L; Möllenhoff K; Dette H; Mentré F AAPS J; 2020 Oct; 22(6):141. PubMed ID: 33125589 [TBL] [Abstract][Full Text] [Related]
5. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs. Rasmussen HE; Ma R; Wang JJ Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634 [TBL] [Abstract][Full Text] [Related]
7. On statistical power for average bioequivalence testing under replicated crossover designs. Wan H; Chow SC J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572 [TBL] [Abstract][Full Text] [Related]
8. Model-based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging? Philipp M; Tessier A; Donnelly M; Fang L; Feng K; Zhao L; Grosser S; Sun G; Sun W; Mentré F; Bertrand J Stat Med; 2024 Aug; 43(18):3403-3416. PubMed ID: 38847215 [TBL] [Abstract][Full Text] [Related]
9. The effect of variability and carryover on average bioequivalence assessment: a simulation study. Sánchez MP; Ocaña J; Carrasco JL Pharm Stat; 2011; 10(2):135-42. PubMed ID: 22432131 [TBL] [Abstract][Full Text] [Related]
10. Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations. Hughes JH; Upton RN; Foster DJR J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):233-244. PubMed ID: 28194623 [TBL] [Abstract][Full Text] [Related]
11. New approach to assess bioequivalence parameters using generalized gamma mixed-effect model (model-based asymptotic bioequivalence test). Chen YI; Huang CS Stat Med; 2014 Feb; 33(5):786-97. PubMed ID: 24105871 [TBL] [Abstract][Full Text] [Related]
12. Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test. Xu XS; Yuan M; Yang H; Feng Y; Xu J; Pinheiro J AAPS J; 2017 Jan; 19(1):264-273. PubMed ID: 27761720 [TBL] [Abstract][Full Text] [Related]
13. Use of the repeated cross-over designs in assessing bioequivalence. Liu JP Stat Med; 1995 May 15-30; 14(9-10):1067-78; discussion 1079-80. PubMed ID: 7569501 [TBL] [Abstract][Full Text] [Related]
14. Inflation of the type I error: investigations on regulatory recommendations for bioequivalence of highly variable drugs. Wonnemann M; Frömke C; Koch A Pharm Res; 2015 Jan; 32(1):135-43. PubMed ID: 25033764 [TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
16. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence. Maurer W; Jones B; Chen Y Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835 [TBL] [Abstract][Full Text] [Related]
17. Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients. Panhard X; Taburet AM; Piketti C; Mentré F Stat Med; 2007 Mar; 26(6):1268-84. PubMed ID: 16810714 [TBL] [Abstract][Full Text] [Related]
18. Equivalence tests for ratio of means in bioequivalence studies under crossover design. He Y; Deng Y; You C; Zhou XH Stat Methods Med Res; 2022 Jul; 31(7):1405-1419. PubMed ID: 35422161 [TBL] [Abstract][Full Text] [Related]
19. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs. Jaki T; Pallmann P; Wolfsegger MJ Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. Bertrand J; Comets E; Laffont CM; Chenel M; Mentré F J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):317-39. PubMed ID: 19562469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]